Endocrinology Search
Endocrinology Endocrinology
diabetes%20mellitus
DIABETES MELLITUS
Diabetes mellitus (DM) is a heterogenous metabolic disorder characterized by the presence of hyperglycemia with carbohydrate, protein and fat metabolism disturbance which results from defects in either insulin secretion or action.
Patients with DM usually present with polyuria, polydipsia and unexplained weight loss.
Type 1 DM is caused by beta cell destruction which leads to complete insulin deficiency. It may be immune mediated or idiopathic.
Patients may present with ketoacidosis or acute onset of hyperglycemia while other patients may resemble type 2 DM or symptoms of other autoimmune disorders.
Type 2 DM is the most common form of diabetes. It is secondary to defect in insulin secretion concomitant with insulin resistance.
Majority of patients are asymptomatic. Ketoacidosis is uncommon and is usually secondary to stress (eg infection).
Drug Information

Indication: NIDDM (type 2) in adults when dietary measures, physical exercise & wt loss alone are not sufficient to co...

Indication: Adjunct to diet & exercise to improve glycaemic control in adults ≥18 yr w/ type 2 DM as monotherapy; a...

Indication: Type 2 DM in adult particularly in overwt patients when dietary management & exercise alone does not resul...

Glyxambi
empagliflozin + linagliptin

Indication: Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM when treatment w/ both empag...

Indication: Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to die...

Indication: Type 2 DM as monotherapy in patients inadequately controlled by diet & exercise alone & for whom metfo...

Indication: Adjunct to diet & exercise to improve glycaemic control in adult patients w/ type 2 DM when treatment w/ b...

Lusefi
luseogliflozin hydrate

Indication: Monotherapy or add-on combination therapy w/ sulfonylurea in adult patients w/ type 2 DM.

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM as monotherapy or as add-on ...

1  /  17
1  /  17
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Febuxostat bests allopurinol, benzbromarone in lowering cholesterol, triglycerides in gout patients
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Weight loss could sustain T2D remission for 2 years
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

Original New Drug Application Approvals by US FDA (16 - 31 July 2019)
31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Long-term cortisol exposure tied to short stature, increased cholesterol in Turner syndrome
6 days ago
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.